N-tert.-Butyl-fluoracetamid | 53848-61-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-tert.-Butyl-fluoracetamid
• 英文别名: N-tert-butyl-2-fluoroacetamide
• CAS: 53848-61-6
• 化学式: C₆H₁₂FNO
• 分子量: 133.166
• InChiKey: AYKGETMYUJMYNM-UHFFFAOYSA-N

物化性质

• 沸点：
  224.0±15.0 °C(Predicted)
• 密度：
  0.957±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  氟代乙酰氯 、 叔丁胺 在 氢氧化钾 作用下， 以 乙醚 为溶剂， 反应 5.0h， 以59%的产率得到N-tert.-Butyl-fluoracetamid
  参考文献：
  名称：

  Synthesis of some new N-monosubstituted fluoroacetamides

  摘要：

  Twenty new N-monosubstituted fluoroacetamides with potential toxicological proper-ties have been synthesized by acylation of the corresponding amines with fluoroacetyl chloride. The substituents were cycloalkyl or various alkyl (with straight or branched carbon chain) groups. The yields ranged from 50 to 92%.

  DOI：

  10.1016/s0022-1139(00)82416-1

文献信息

• PTERIDINE KETONE DERIVATIVE AND APPLICATIONS THEREOF AS EGFR, BLK, AND FLT3 INHIBITOR
  申请人：EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY

  公开号：US20150126508A1

  公开（公告）日：2015-05-07

  Provided are a pteridine ketone derivative used as an EGFR, BLK, and FLT3 inhibitor and applications thereof. Specifically, provided are a compound of the following formula I, a pharmaceutical composition containing the compound of the formula I, and use of compound in preparing medicine for treating diseases mediated by EGFR, BLK, or FLT3 or inhibiting EGFR, BLK, and FLT3.

  提供了一种吡哌啶酮衍生物，用作EGFR、BLK和FLT3抑制剂及其应用。具体而言，提供了以下结构式I的化合物，含有该化合物的药物组合物，以及将该化合物用于制备治疗由EGFR、BLK或FLT3介导的疾病或抑制EGFR、BLK和FLT3的药物的用途。
• PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS
  申请人：Baroudy Bahige M.

  公开号：US20080188485A1

  公开（公告）日：2008-08-07

  The use of CCR 5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R 1 is hydrogen or alkyl; R 2 is substituted phenyl, substituted heteroaryl, naphthyl fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroarylalkyl; R 3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R 4 , R 5 and R 7 are hydrogen or alkyl; R 6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.

  本发明涉及CCR5拮抗剂的使用，其化学式为或其药学上可接受的盐，其中R是可选的取代苯基、吡啶基、噻吩基或萘基；R1是氢或烷基；R2是取代苯基、取代杂环芳基、萘基、芴基、二苯甲基或可选取代的苯基或杂环芳基烷基；R3是氢、烷基、烷氧基烷基、环烷基、环烷基烷基或可选取代的苯基、苯基烷基、萘基、萘基烷基、杂环芳基或杂环芳基烷基；R4、R5和R7是氢或烷基；R6是氢、烷基或烯基；用于治疗HIV、固体器官移植排斥、移植物抗宿主病、关节炎、类风湿性关节炎、炎症性肠病、特应性皮炎、牛皮癣、哮喘、过敏或多发性硬化症，以及新型化合物、包含它们的药物组合物，以及本发明的CCR5拮抗剂与用于治疗HIV或治疗炎症性疾病的抗病毒药物的组合。
• [EN] COMBINATION OF AN ERK INHIBITOR AND A KRAS INHIBITOR AND USES THEREOF<br/>[FR] COMBINAISON D'UN INHIBITEUR D'ERK ET D'UN INHIBITEUR DE KRAS ET SES UTILISATIONS
  申请人：SHANGHAI ANTENGENE CORPORATION LTD

  公开号：WO2022262797A1

  公开（公告）日：2022-12-22

  The present disclosure generally relates to the combination of an ERK inhibitor and a KRAS inhibitor, and use thereof.

  本公开涉及ERK抑制剂和KRAS抑制剂的组合及其使用。
• Substituted quinazoline compounds and methods of use thereof
  申请人：Araxes Pharma LLC

  公开号：US10246424B2

  公开（公告）日：2019-04-02

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have one of the following structures (I), (II) or (III): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R1, R2a, R2b, R2c, R3a, R3b, R4a, R4b, R5a, R5b, R6, A, B, G1, G2, L1, L2, m1, m2, n, x, y, X and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

  本研究提供了具有抑制 G12C 突变 KRAS 蛋白活性的化合物。这些化合物具有以下结构之一 (I)、(II) 或 (III)： 或其药学上可接受的盐、立体异构体或原药，其中 R1、R2a、R2b、R2c、R3a、R3b、R4a、R4b、R5a、R5b、R6、A、B、G1、G2、L1、L2、m1、m2、n、x、y、X 和 E 如本文所定义。还提供了与制备和使用此类化合物相关的方法、包含此类化合物的药物组合物以及调节G12C突变型KRAS蛋白活性以治疗疾病（如癌症）的方法。
• Inhibitors of KRAS G12C mutant proteins
  申请人：Araxes Pharma LLC

  公开号：US10280172B2

  公开（公告）日：2019-05-07

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein B, W, X, Y, R1, R2a, R2b, R3a, R3b, R4a, R4b, G1, G2, m1, m2, L1, L2 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

  本研究提供了具有抑制 G12C 突变 KRAS 蛋白活性的化合物。这些化合物具有以下结构 (I)： 或其药学上可接受的盐、同系物、立体异构体或原药，其中 B、W、X、Y、R1、R2a、R2b、R3a、R3b、R4a、R4b、G1、G2、m1、m2、L1、L2 和 E 如本文所定义。还提供了与制备和使用此类化合物相关的方法、包含此类化合物的药物组合物以及调节 G12C 突变 KRAS 蛋白活性以治疗疾病（如癌症）的方法。